Real-World Evidence Registry Aims To Build Research Credibility Through Transparency
Executive Summary
Pre-registration of study protocols will be voluntary and concerns with revealing proprietary information, among other issues, could be a deterrent to participation. But the developers of the registry hope that researchers will conclude the benefits of doing so outweigh the risks.
You may also be interested in...
Real-World Evidence: ‘Labor-Intensive’ Data Standardization May Be Required By US FDA
New draft guidance offers recommendations for translating real-world data from claims or EHR sources to meet FDA data requirements.
Real-World Evidence Study Registration May Help Drive FDA Acceptance
US FDA’s David Martin encourages sponsors to register observational studies on drug effectiveness to enhance transparency and agency confidence in the data.
Merck’s Winrevair Well Positioned To Benefit From Medicare Part D Redesign
Significant cost sharing reductions under the redesign will enhance uptake of the pulmonary arterial hypertension drug. The trade-off is a 20% mandatory price discount in the catastrophic phase.